Early Prediction of Severe Icans after CD19 CAR T-Cell Therapy Based on Serum Ferritin Levels
Jennifer J. Huang(University of Washington), Jordan Gauthier(Seattle Cancer Care Alliance), David G. Maloney(Fred Hutch Cancer Center), Delaney R. Kirchmeier(Fred Hutch Cancer Center), Natalie Wuliji(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Aiko Torkelson(Fred Hutch Cancer Center), Andrew J. Portuguese(University of Washington), Aude G. Chapuis(University of Washington), Brian G. Till(University of Washington), Alexandre V. Hirayama(University of Washington), Mazyar Shadman(University of Washington), Filippo Milano(Fred Hutch Cancer Center), Lorenzo Iovino(University of Pisa), Folashade Otegbeye(University Hospitals of Cleveland), Aya Albittar(University of Washington), Ryan D. Cassaday(University of Washington), Emily C. Liang(Fred Hutch Cancer Center), Cameron J. Turtle(The University of Sydney), Abigail Chutnik(Fred Hutch Cancer Center), Barbara S. Pender, Erik L. Kimble(University of Washington)
Cited by 3
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy
|Blood|2017|1.1k